1 / 10

Personalized Medicine Diagnostic Market

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented

bharatbookseo
Download Presentation

Personalized Medicine Diagnostic Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PersonAalized Medicine Diagnostic Market www.bharatbook.com

  2. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented as follows: This detailed report is supported with 360 figures and tables over 397 pages and profiles the main pharmacies in personalized medicine.

  3. Executive Summary The companion diagnostic and targeted therapeutic submarkets of the personalized medicine industry were worth $113 billion in 2016, and will hit over $162 billion by 2021 with a CAGR of 8.74%. The total personalized therapeutic market, for all indications, will be worth $ billion by 2021, with a CAGR of %. Currently it is estimated that the companion diagnostic segment is worth $ billion globally, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. This is set to rise vertically over the next five years and by 2021 will be worth over $ billion, with a CAGR of %.

  4. This study details a comprehensive financial and strategic review of key players in the personalized medicine industry. Significant drivers and restraints of this market are revealed and market opportunities and challenges are identified. Disruptive technologies that are propelling the personalized medicine and companion diagnostic market are scrutinized. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today.

  5. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analyzed. This study reveals market figures of the overall personalized medicine market and also sub-markets figures with respect to companion diagnostics, targeted cancer therapeutics, medical technologies, pharmacogenomics, consumer genomics, molecular diagnostics and liquid biopsies. Specific indication markets are also included such as cancer, cardiovascular and infectious disease.

  6. The report provides value and growth of the global personal therapeutics market from 2017-2021. Also historic figures back to 2014 are given to illustrate growth. As the personal targeted therapeutics market is part of the overall personalized medicine market, the companion diagnostics market is also included in the report The report goes into detail regarding different indications, mainly oncology drugs as these hold most market share, and also cardiovascular and infectious disease markets. It contains specific data for both the targeted therapeutic and companion diagnostic sections of the personalized medicine market.

  7. Targeted Cancer Therapeutics Targeted cancer therapeutic sales have significantly risen in the recent past with a x% increase from 2013 to 2014 alone. The global oncology market is currently booming and one of the main reasons for this increase is the dramatic rise in the number of prescribed targeted therapies. The market is also growing in size as the cost of targeted therapeutics is high. This is due to longer treatment times, increased investment and development costs. Targeted therapeutics also are, by definition, designed to treat smaller cohorts of patients, albeit more effectively. Therefore, pharmacy’s need to recoup costs via pricing.

  8. Two major targeted therapeutics on the market are Roche’s melanoma agent Zelboraf and Pfizer’s lung cancer agent Xalkori. Zelboraf (vemurafenib) is a MEK inhibitor indicated for skin cancer and in FY2013 reached $x million. Xalkori (crizotinib) is indicated in patients positive for an ALK mutation and has an annual sale figure of €x million.

  9. More Information Personalized Medicine Diagnostic Market Contact us at:Bharat Book BureauTel: +91 22 27810772 / 27810773Email:poonam@bharatbook.comOur Blog:https://www.bharatbook.com/blog/Twitter: https://twitter.com/researchbookFacebook:https://www.facebook.com/BharatBook3BLinkedIn:http://www.linkedin.com/company/bharat-book-bureau

More Related